Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.42 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenyl Methyl Borinic Acid SCHEMBL120622 | 0.84 | — | — | |
| SCHEMBL14407594 | 0.82 | CA2 (0.61) | MGLLCA1CA2CA4CA6 | |
| SCHEMBL24996834 | 0.81 | CA2 (0.45) | MGLLCA1CA2CA4CA6 | |
| SCHEMBL12270787 | 0.80 | CA2 (0.56) | MGLLCA1CA2ALDH1A1ORAI1 | |
| SCHEMBL12860012 | 0.79 | CA2 (1.00) | MGLLCA1CA2MMP3BCL2L1 | |
| SCHEMBL25665366 | 0.79 | CA2 (1.00) | MGLLCA1CA2MMP3BCL2L1 | |
| Biphenylboronic Acid SCHEMBL129728 | 0.79 | CA2 (1.00) | MGLLCA1CA2MMP3BCL2L1 | |
| Tannin Pyrogallol SCHEMBL5476910 | 0.78 | MGLL (0.68) | MGLLCA1CA2MMP3BCL2L1 | |
| SCHEMBL2407457 | 0.77 | TRPV6 (0.74) | MGLLCA1CA2MMP3BCL2L1 | |
| SCHEMBL15459224 | 0.76 | CA2 (0.54) | MGLLCA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096857-A1 | Aldose-Ketose Transformation for Separation and/or Chemical Conversion of C6 and C5 Sugars from Biomass Materials | THE UNIVERSITY OF TOLEDO (US) | 2016-04-07 | — | — | US | disclosed |
| US-9242222-B2 | Aldose-ketose transformation for separation and/or chemical conversion of C6 and C5 sugars from biomass materials | THE UNIVERSITY OF TOLEDO (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150275076-A1 | Non-crystallizable Pi-conjugated Molecular Glass Mixtures, Charge Transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-10-01 | — | — | US | disclosed |
| US-20130074397-A1 | Aldose-Ketose Transformation for Separation and/or Chemical Conversion of C6 and C5 Sugars from Biomass Materials | UNIVERSITY OF TOLEDO (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120142872-A1 | PROCESS FOR POLYMERISING (HETERO)AROMATIC COMPOUNDS | BASF SE (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-1765358-B1 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7888356-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7652000-B2 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1765360-B1 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2044091-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | Anacor Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1765360-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765358-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006085932-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060009422-A1 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005123094-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | MGLL 4560/4885CA1 1384/4885CA2 293/4885 |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | MGLL 3746/4885CA1 649/4885CA2 78/4885 |
| US-20060009422-A1 | Boron-containing compounds and methods of use | BROX, BTD, PBDC1 | MGLL 3607/4885CA1 1299/4885CA2 626/4885 |
| US-20160096857-A1 | Aldose-Ketose Transformation for Separation and/or Chemical Conversion of C6 and C5 Sugars from Biomass Materials | ALDOA, HK1, KHK | MGLL 1098/4885CA1 1110/4885CA2 1121/4885 |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | MGLL 4560/4885CA1 1384/4885CA2 293/4885 |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | SSB, BPGM, HAVCR2 | MGLL 4257/4885CA1 602/4885CA2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.